Base de dados : MEDLINE
Pesquisa : C04.588.945.947 [Categoria DeCS]
Referências encontradas : 3966 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 397 ir para página                         

  1 / 3966 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29399882
[Au] Autor:Mitra S; Chatterjee D; Das A; Gupta K; Radotra BD; Mandal AK
[Ad] Endereço:Department of Histopathology, PGIMER, Chandigarh, India.
[Ti] Título:Urothelial tumors with villous morphology: Histomorphology and role of immunohistochemistry in diagnosis.
[So] Source:APMIS;126(3):191-200, 2018 Mar.
[Is] ISSN:1600-0463
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:Villous adenoma and urothelial carcinoma with villoglandular differentiation (UCVGD) are rare urothelial tumours showing villous morphology, the former being a preneoplastic entity and the latter being a malignant one. The detailed immunohistochemistry of these entities is previously not described in the literature. Moreover, a limited biopsy sample of UCVGD or a villous adenoma with or without adenocarcinoma may be difficult to distinguish on the basis of the histomorphology alone. An immunohistochemical panel comprising of GATA3, p63, ß-catenin, CK7 and CK20 was performed on five cases of UCVGD and three cases of villous adenoma with the aim of studying the expression of the proteins thereby aiding in the diagnosis of these entities in a limited surgical pathology specimen. The mean age of UCVGD was 66.8 years and all the patients were male. All the cases of UCVGD were associated with high grade papillary urothelial carcinoma with lamina propria invasion. The immunohistochemical panel showed strong nuclear GATA3 expression in the urothelial component of UCVGD. Interestingly, the high grade and the low grade villoglandular components of UCVGD also expressed GATA3 (nuclear) with a progressive loss of expression from the high grade to the low grade component. The villous adenomas showed negativity or aberrant cytoplasmic positivity for GATA3. The ß-catenin showed a gradual loss of membranous expression from villous adenoma to low grade and high grade villoglandular components of UCVGD with a patchy membranous expression in the urothelial component of the UCVGD. p63 showed strong nuclear positivity in the urothelial component and uniform negativity in the villous adenoma and villoglandular component of UCVGD irrespective of its grade, thereby distinguishing the villoglandular component from the urothelial component. The urothelial component of UCVGD showed strong membranous CK7 expression and was higher than the CK20 expression in the urothelial component. In contrast, CK20 expression was higher in villous adenoma as compared to CK7. There was no difference in the expression of CK7 and CK20 in the villoglandular components and low grade and high grade villoglandular areas. The above-mentioned immunohistochemical pattern may help to distinguish the UCVGD from the villous adenoma.
[Mh] Termos MeSH primário: Adenoma Viloso/diagnóstico
Fator de Transcrição GATA3/metabolismo
Queratina-7/metabolismo
Proteínas de Membrana/metabolismo
Neoplasias Urológicas/diagnóstico
beta Catenina/metabolismo
[Mh] Termos MeSH secundário: Adenoma Viloso/patologia
Idoso
Biomarcadores Tumorais/metabolismo
Feminino
Hematúria/patologia
Seres Humanos
Imuno-Histoquímica
Queratina-20/metabolismo
Masculino
Meia-Idade
Neoplasias Urológicas/patologia
Urotélio/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CKAP4 protein, human); 0 (GATA3 Transcription Factor); 0 (GATA3 protein, human); 0 (KRT20 protein, human); 0 (KRT7 protein, human); 0 (Keratin-20); 0 (Keratin-7); 0 (Membrane Proteins); 0 (beta Catenin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.1111/apm.12799


  2 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777772
[Au] Autor:Michel Ortega RM; Wolff DJ; Schandl CA; Drabkin HA
[Ad] Endereço:Division of Hematology and Oncology, Medical University of South Carolina, 173 Ashley Ave, Suite 102 BSB, Charleston, SC 29425 USA.
[Ti] Título:Urothelial carcinoma of donor origin in a kidney transplant patient.
[So] Source:J Immunother Cancer;4:63, 2016.
[Is] ISSN:2051-1426
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant state. Donor-derived malignancy is a rare reported complication. Herein, we review our patient history and discuss diagnostic strategies and the implications of immunosuppression for donor-derived malignancy. CASE PRESENTATION: This is a 69-year-old man with post-renal-transplant urothelial carcinoma determined to be of donor origin. His course was complicated by BK virus at six years post-transplant; urothelial carcinoma was identified nine years post-transplant. Cystectomy was performed, but because of immunosuppression and underlying chronic kidney disease, the patient was considered ineligible for adjuvant chemotherapy. Two years after resection, screening MRI demonstrated retroperitoneal lymphadenopathy and a right upper pole mass in the transplanted kidney. Urine cytology confirmed the presence of malignant cells; FISH showed 2-8 copies of the X chromosome and no Y chromosome consistent with female origin of the malignant cells. CT-guided renal mass and paraaortic lymph node biopsies demonstrated that about 50 % of cells had an XY complement, while the remainder showed a XX genotype by chromosomal SNP microarray analysis. Immunosuppression was discontinued and the donor kidney removed. X/Y FISH of the urothelial carcinoma identified in the explanted kidney confirmed that the malignant cells were of female donor origin. Follow-up at 3, 6 and 12 months after discontinuation of immunosuppression and surgery demonstrated normalization of the lymphadenopathy and absence of new lesions. CONCLUSIONS: Immunosuppression is a major risk factor for development of malignancy in transplant recipients. Donor-derived malignancy can arise and current molecular studies allow an accurate diagnosis. Withdrawal of immunosuppression and surgical resection of the transplant kidney proved an effective treatment in our case.
[Mh] Termos MeSH primário: Transplante de Rim/efeitos adversos
Doadores de Tecidos
Neoplasias Urológicas/diagnóstico
Neoplasias Urológicas/etiologia
[Mh] Termos MeSH secundário: Idoso
Vírus BK
Aberrações Cromossômicas
Seres Humanos
Imunossupressão
Imunossupressores/efeitos adversos
Hibridização in Situ Fluorescente
Imagem por Ressonância Magnética
Masculino
Infecções por Polyomavirus/complicações
Infecções por Polyomavirus/virologia
Tomografia Computadorizada por Raios X
Transplante Homólogo
Infecções Tumorais por Vírus/complicações
Infecções Tumorais por Vírus/virologia
Neoplasias Urológicas/genética
Neoplasias Urológicas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  3 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29061830
[Au] Autor:Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
[Ad] Endereço:Department of Urology/Pediatric Urology, Philipps University, Marburg, Germany.
[Ti] Título:Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
[So] Source:Anticancer Res;37(11):6437-6442, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment. PATIENTS AND METHODS: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed. RESULTS: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively. The effectiveness of vinflunine treatment was comparable with an overall response rate of 22.2% and 23.7% respectively and a median progression-free survival of 2.76 months in both groups. Median overall survival was 5.0 months in UTUC compared to 8.2 months in the LTUC group (p=0.478). The safety profile was in accordance with previous vinflunine experiences, with a comparable frequency of adverse events in both groups. CONCLUSION: Vinflunine can be applied in the 2nd line for UC regardless of the primary tumor localization.
[Mh] Termos MeSH primário: Antineoplásicos Fitogênicos/administração & dosagem
Carcinoma de Células de Transição/tratamento farmacológico
Neoplasias Urológicas/tratamento farmacológico
Vimblastina/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos Fitogênicos/uso terapêutico
Carcinoma de Células de Transição/patologia
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Metástase Neoplásica
Prognóstico
Estudos Prospectivos
Análise de Sobrevida
Resultado do Tratamento
Neoplasias Urológicas/patologia
Vimblastina/administração & dosagem
Vimblastina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents, Phytogenic); 5BF646324K (vinflunine); 5V9KLZ54CY (Vinblastine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  4 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802562
[Au] Autor:Cao Z; Wu S
[Ad] Endereço:Department of Urological Surgery, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, 518000, China; Medical College, Shenzhen University, Shenzhen, 518000, China; Shenzhen Following Precision Medical Institute, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, 518000, China.
[Ti] Título:Current research development of single cell genome in urological tumor.
[So] Source:Int J Biochem Cell Biol;90:167-171, 2017 Sep.
[Is] ISSN:1878-5875
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The technique of whole genome amplification is advancing rapidly and generating attention on detecting genomic lesions in individual cancer cells. Also, single-cell genome could label the uniqueness of each cell, its individual mutations and structural variations especially in cancer studies. In this Review, we provide the insight into the current state of single-cell genome in urological tumor mainly including kidney cancer, bladder cancer and prostate cancer. We put more forward on the new progress of the technique used by single-cell genomes and different results of the genes transform on random tumor tissue from single cell isolated on account of tumor heterogeneity. With the advent of more complete and accurate genome information, single-cell sequencing will become a standard tool in early diagnosis and targeted therapy and prognosis judgement.
[Mh] Termos MeSH primário: Genômica/métodos
Análise de Célula Única/métodos
Neoplasias Urológicas/genética
Neoplasias Urológicas/patologia
[Mh] Termos MeSH secundário: Animais
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  5 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28637566
[Au] Autor:Hamner JB; Raoof M; Dumitra S; Schoellhammer HF; Crowder C; Ituarte PHG; Kim J; Singh G
[Ti] Título:Evolving Role of Hepatic Resection for Metastatic Urologic Malignancies.
[So] Source:Am Surg;83(6):628-632, 2017 Jun 01.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liver resection for noncolorectal, nonneuroendocrine metastases remains controversial. Here, we evaluate a single institutional experience with hepatic resection for metastatic urologic malignancies. A single-institution review of patients who underwent hepatic resection for metastatic urologic tumors between the years of 2000 and 2013 was performed. Patient charts were analyzed for pathologic data and perioperative outcomes including short- and long-term morbidity, mortality, and overall and disease-free survival. Eleven patients were identified who underwent hepatic resection for metastatic urologic malignancy. The mean age was 63.5 years. All patients had an R0 resection. There were three major complications. Mean length of stay was 6.5 days and there was no 90-day mortality. Three patients have died of recurrent disease at an average of 11.2 months from resection to death. The remaining patients are still alive during a mean follow-up of 31.5 months. Five-year overall and disease-free survival was 50 and 21 months, respectively. Hepatic resection for metastatic urologic tumors is safe with low morbidity and mortality and durable long-term survival can be achieved. Liver resection for isolated hepatic disease should be considered for this rare metastatic disease to the liver.
[Mh] Termos MeSH primário: Hepatectomia
Neoplasias Hepáticas/secundário
Neoplasias Hepáticas/cirurgia
Recidiva Local de Neoplasia/secundário
Recidiva Local de Neoplasia/cirurgia
Neoplasias Urológicas/patologia
Neoplasias Urológicas/cirurgia
[Mh] Termos MeSH secundário: Idoso
Intervalo Livre de Doença
Feminino
Seguimentos
Hepatectomia/métodos
Seres Humanos
Neoplasias Hepáticas/mortalidade
Masculino
Meia-Idade
Recidiva Local de Neoplasia/mortalidade
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Neoplasias Urológicas/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE


  6 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28632777
[Au] Autor:Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J; Bridge Consortium
[Ad] Endereço:Department of Urology and Pediatric Urology, University Hospital Erlangen, Erlangen, Germany.
[Ti] Título:Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
[So] Source:PLoS One;12(6):e0179602, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Genome-wide analyses revealed basal and luminal subtypes of urothelial carcinomas of the bladder. It is unknown if this subtyping can also be applied to upper tract urothelial carcinomas. MATERIALS AND METHODS: Tumor samples from 222 patients with upper tract urothelial carcinomas who were treated with radical nephroureterectomy were analyzed for the expression of seven basal/luminal immunohistochemical markers (CK5, EGFR, CD44, CK20, p63, GATA3, FOXA1). RESULTS: Hierarchical clustering revealed a basal-like subtype (enrichment of CK5, EGFR and CD44) in 23.9% and a luminal-like subtype (enrichment of CK20, GATA3, p63 and FOXA1) in 13.1% of the patients. In 60.8%, little to no markers were expressed, whereas markers of both subtypes were expressed in 2.2%. By using CK5 and CK20 as surrogate markers for the basal and luminal subtypes, we defined four subtypes of upper tract urothelial carcinomas: (i) exclusively CK20 positive and CK5 negative (CK20+/CK5-), (ii) exclusively CK5 positive and CK20 negative (CK20-/ CK5+), (iii) both markers positive (CK20+/CK5+) and (iv) both markers negative (CK20-/CK5-). A receiver-operator analysis provided the optimal cut-off values for this discrimination. An immunoreactive score >1 for CK5 and >6 for CK20 were defined as positive. In multivariate Cox's regression analysis, the CK20+/CK5- subtype was an independent negative prognostic marker with a 3.83-fold increased risk of cancer-specific death (p = 0.02) compared to the other three subtypes. CONCLUSIONS: Immunohistochemical subgrouping of upper tract urothelial carcinomas by analyzing CK5 and CK20 expression can be performed in a routine setting and can identify tumors with a significantly worse cancer-specific survival prognosis.
[Mh] Termos MeSH primário: Carcinoma/patologia
Queratina-20/metabolismo
Queratina-5/metabolismo
Neoplasias Urológicas/patologia
[Mh] Termos MeSH secundário: Idoso
Área Sob a Curva
Biomarcadores Tumorais/metabolismo
Carcinoma/metabolismo
Carcinoma/mortalidade
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Prognóstico
Modelos de Riscos Proporcionais
Curva ROC
Estudos Retrospectivos
Taxa de Sobrevida
Neoplasias Urológicas/metabolismo
Neoplasias Urológicas/mortalidade
Urotélio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Keratin-20); 0 (Keratin-5)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179602


  7 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28601179
[Au] Autor:George M; Perez-Rosello JM; Yikilmaz A; Lee EY
[Ad] Endereço:Department of Radiology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: Michael.George@childrens.harvard.edu.
[Ti] Título:Pediatric Urinary System Neoplasms: An Overview and Update.
[So] Source:Radiol Clin North Am;55(4):767-784, 2017 Jul.
[Is] ISSN:1557-8275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pediatric urinary system neoplasms are a diverse group of tumors that frequently overlap in their clinical and radiologic features. By contrast, the histopathologic classification and treatment of these entities have become increasingly refined, resulting in improved outcomes, with the overall survival of Wilms tumors now exceeding 90%. Significantly, many contemporary protocols rely on radiologic diagnosis in the absence of tissue confirmation. This review article provides up-to-date clinical, epidemiologic, and imaging findings of pediatric urinary system neoplasms and their mimics frequently encountered in daily clinical practice.
[Mh] Termos MeSH primário: Diagnóstico por Imagem/métodos
Neoplasias Urológicas/diagnóstico por imagem
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Diagnóstico Diferencial
Seres Humanos
Lactente
Recém-Nascido
Neoplasias Urológicas/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE


  8 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594151
[Au] Autor:Venniyoor A
[Ad] Endereço:Royal Hospital, Muscat, Oman avenniyoor@gmail.com
[Ti] Título:Pembrolizumab for Advanced Urothelial Carcinoma.
[So] Source:N Engl J Med;376(23):2302-3, 2017 06 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados
Carcinoma de Células de Transição
[Mh] Termos MeSH secundário: Anticorpos Monoclonais
Seres Humanos
Neoplasias Urológicas
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1704612


  9 / 3966 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28593860
[Au] Autor:Wong YNS; Joshi K; Pule M; Peggs KS; Swanton C; Quezada SA; Linch M
[Ad] Endereço:Department of Oncology, University College London Cancer Institute, London, UK; Immune Regulation and Tumour Immunotherapy Laboratory, University College London Cancer Institute, London, UK; Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, UK.
[Ti] Título:Evolving adoptive cellular therapies in urological malignancies.
[So] Source:Lancet Oncol;18(6):e341-e353, 2017 Jun.
[Is] ISSN:1474-5488
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Immunotherapies have long been used to treat urological cancers but rarely lead to cure. In the past 5 years, success of immune checkpoint inhibition has led to a resurgence of enthusiasm for immunotherapy in the treatment of solid tumours. Increased understanding of tumour immune biology, technological advancements of gene transfer and cell culture, and improved clinical infrastructures for routine delivery of cell products, has made cell-based immunotherapeutics a real prospect for cancer therapy. These scientific and clinical activities, attempting to exploit the innate and adaptive immune systems for therapeutic gain, are well exemplified by the urological malignancies of renal, bladder, prostate, and penile cancer, a group of anatomically localised diseases, each with a distinct biology and different immunotherapeutic challenges. In this Review, we present the results of clinical studies investigating autologous cellular therapies in urological malignancies. Specifically, we discuss the rationale for upcoming studies, and how novel therapies and adoptive cell combinations can be used for personalised cancer therapy.
[Mh] Termos MeSH primário: Imunidade Adaptativa
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Imunidade Inata
Imunoterapia Adotiva
Neoplasias Urológicas/terapia
[Mh] Termos MeSH secundário: Terapia Combinada
Células Dendríticas/imunologia
Seres Humanos
Células Matadoras Naturais/imunologia
Linfócitos T/imunologia
Neoplasias Urológicas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE


  10 / 3966 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28591526
[Au] Autor:Bellmunt J; Bajorin DF
[Ad] Endereço:Dana-Farber Cancer Institute, Boston, MA joaquim_bellmunt@dfci.harvard.edu.
[Ti] Título:Pembrolizumab for Advanced Urothelial Carcinoma.
[So] Source:N Engl J Med;376(23):2304, 2017 06 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados
Neoplasias Urológicas
[Mh] Termos MeSH secundário: Anticorpos Monoclonais
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1704612



página 1 de 397 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde